Corvus Pharmaceuticals’ (CRVS) Neutral Rating Reaffirmed at Mizuho

Mizuho reaffirmed their neutral rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a research note released on Wednesday, Benzinga reports. They currently have a $3.50 price target on the stock.

Separately, Oppenheimer lowered their price objective on Corvus Pharmaceuticals from $8.00 to $7.00 and set an outperform rating on the stock in a research report on Wednesday, March 20th.

Corvus Pharmaceuticals Stock Performance

Shares of Corvus Pharmaceuticals stock opened at $1.79 on Wednesday. The company has a 50-day simple moving average of $2.09 and a two-hundred day simple moving average of $1.75. Corvus Pharmaceuticals has a 52-week low of $0.61 and a 52-week high of $4.19. The stock has a market capitalization of $87.78 million, a PE ratio of -3.14 and a beta of 1.04.

Institutional Trading of Corvus Pharmaceuticals

A number of large investors have recently made changes to their positions in CRVS. Tucker Asset Management LLC purchased a new stake in Corvus Pharmaceuticals in the second quarter worth approximately $29,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth $36,000. American Century Companies Inc. bought a new stake in shares of Corvus Pharmaceuticals in the third quarter worth $27,000. Tower Research Capital LLC TRC increased its position in Corvus Pharmaceuticals by 63.1% during the second quarter. Tower Research Capital LLC TRC now owns 20,543 shares of the company’s stock valued at $47,000 after acquiring an additional 7,946 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Corvus Pharmaceuticals in the second quarter valued at about $49,000. 46.64% of the stock is currently owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers.